Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Moody's Investor Services, raising the company's corporate credit rating to Ba1 with a stable outlook from Ba2 with a positive outlook. The upgrade reflects Teva's significant global presence, growth in branded franchises, stabilization of its generics business, and successful debt reduction efforts. According to CFO Eli Kalif, this upgrade validates the success of Teva's Pivot to Growth strategy and is expected to result in improved debt costs and broader access to investors.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its upcoming Innovation & Strategy Day, scheduled for Thursday, May 29, 2025, in New York City. The event will run from 8:30 AM to 12:30 PM Eastern Time. CEO Richard Francis and the executive management team will present updates on the company's strategy, focusing on the acceleration phase, growth initiatives, and innovation priorities.
Due to limited capacity, in-person attendance is invitation-only, with analysts and institutional investors requiring pre-registration. A live webcast will be available on Teva's Investor Relations website, with archived content accessible within 24 hours after the event.
Teva Pharmaceuticals and Samsung Bioepis have announced the U.S. availability of EPYSQLI® (eculizumab-aagh), a biosimilar to Soliris®. The treatment is now accessible for patients with rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG) in AchR antibody positive adults.
EPYSQLI will be offered at a 30% discount compared to Soliris's Wholesale Acquisition Cost, making it one of the most cost-effective biosimilars in the U.S. The FDA approved EPYSQLI in July 2024 for PNH and aHUS treatments, with gMG indication added in November 2024.
Under their January 2025 partnership, Samsung Bioepis manages development, manufacturing, and supply, while Teva handles U.S. commercialization. The FDA has provisionally determined EPYSQLI to be interchangeable with Soliris® after exclusivity expiration for the first interchangeable biosimilar.
Teva Pharmaceuticals (NYSE: TEVA) announced the FDA's acceptance of its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab) to expand its use to pediatric episodic migraine prevention in patients aged 6-17 years weighing 45kg or more.
The application is supported by positive Phase 3 SPACE trial results, which showed statistically significant improvements in reducing monthly migraine and headache days versus placebo. If approved, AJOVY would become the first calcitonin gene-related peptide (CGRP) antagonist for both adult migraine prevention and pediatric episodic migraine prevention.
AJOVY, initially approved in the U.S. in 2018 for adult migraine prevention, is currently the only anti-CGRP treatment available in both quarterly and monthly dosing options. The treatment is also approved in Europe, Canada, Australia, and Japan.
Teva Pharmaceuticals has announced promising results from their Phase 3 SOLARIS trial survey for TEV-'749, a once-monthly subcutaneous long-acting injectable treatment for schizophrenia. The survey revealed high satisfaction rates among participants:
- Over 92% of patients were satisfied with the initiation regimen and dosing schedule
- 87% of nurses and 72% of physicians expressed satisfaction with the treatment
- 78.6% of patients preferred subcutaneous over intramuscular injection
The study included 70 patients, 24 nurses, and 11 physicians. Notable findings showed that 90% of patients would prefer an LAI without post-injection monitoring, and 72.9% favored a single-injection initiation regimen. The data was presented at the 2025 SIRS Congress in Chicago, highlighting TEV-'749's potential as a new treatment option for schizophrenia using MedinCell's SteadyTeq™ technology.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced the release of its Q1 2025 Aide Memoire, now available on the company's investor relations webpage. The document is designed to assist in financial modeling of quarterly results, incorporating previous performance data, management commentary on business outlook, and select third-party source information.
The company has indicated its intention to provide this information regularly towards the end of each quarter going forward.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will publish its Q1 2025 financial results press release on Wednesday, May 7, 2025, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day.
Interested participants must register in advance to obtain local or toll-free phone numbers and personal pins. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call conclusion.